A synthetic ERR agonist alleviates metabolic syndrome
Billon C, Schoepke E, Avdagic A, et al.
Journal of Pharmacology and Experimental Therapeutics
Summary
Demonstrated that SLU-PP-332 mimics exercise-induced metabolic benefits in obese mice, including increased energy expenditure, enhanced fatty acid oxidation, decreased fat mass accumulation, and improved insulin sensitivity. Establishes ERR agonism as a viable approach to treat metabolic syndrome.
Key Findings
- SLU-PP-332 increased energy expenditure and fatty acid oxidation in diet-induced obese mice
- Significantly decreased fat mass accumulation without changes in food intake
- Improved insulin sensitivity in multiple models of metabolic syndrome
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function
Xu W, Billon C, Li H, et al.
Circulation
Showed that SLU-PP-332 and its successor SLU-PP-915 significantly improved cardiac ejection fraction, reduced fibrosis, and increased survival in pressure overload-induced heart failure. The ERR-gamma-mediated cardioprotection occurs through enhanced fatty acid metabolism and mitochondrial oxidative capacity.
- SLU-PP-332 improved ejection fraction and increased survival in heart failure model
- Normalized fatty acid and mitochondrial metabolic profiles in failing hearts
Synthetic ERR alpha/beta/gamma agonist induces an ERR-alpha-dependent acute aerobic exercise response and enhances exercise capacity
Billon C, Sitaula S, Banerjee S, et al.
ACS Chemical Biology
First characterization of SLU-PP-332 as a pan-ERR agonist with highest potency for ERR-alpha. Administration to mice increased type IIa oxidative skeletal muscle fibers, enhanced exercise endurance, and activated an acute aerobic exercise genetic program — establishing it as a pharmacological exercise mimetic.
- SLU-PP-332 is a first-in-class pan-ERR agonist targeting all three ERR subtypes
- Increased type IIa oxidative muscle fibers and enhanced exercise endurance in mice